PSPH and melanoma: Similarly, in the PRJEB23709 melanoma anti-PD1 immunotherapy cohort [33], the levels of PSAT1, PSPH, and SHMT1/2 were significantly reduced in PR or CR patients treated with anti-PD1 compared with drug-resistant PD patients (Fig. 7C to F).